Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Pacira BioSciencesAlkermesViela BioRocket PharmaceuticalsMorphoSys
SymbolNASDAQ:PCRXNASDAQ:ALKSNASDAQ:VIENASDAQ:RCKTNASDAQ:MOR
Price Information
Current Price$64.45$20.92$53.01$44.50$23.18
52 Week RangeBuyHoldHoldBuyHold
MarketRank™
Overall Score1.91.20.81.40.3
Analysis Score2.31.01.13.50.0
Community Score2.92.81.22.91.4
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.80.80.0
Earnings & Valuation Score4.40.60.60.00.0
Analyst Ratings
Consensus RecommendationBuyHoldHoldBuyHold
Consensus Price Target$77.50$20.86$57.00$59.18N/A
% Upside from Price Target20.25% upside-0.30% downside7.53% upside32.99% upsideN/A
Trade Information
Market Cap$2.83 billion$3.33 billion$2.91 billion$2.75 billion$3.05 billion
Beta1.271.250.432.051.03
Average Volume489,1721,289,4011,065,058504,38959,327
Sales & Book Value
Annual Revenue$421.03 million$1.17 billion$50 millionN/A$80.43 million
Price / Sales6.712.8458.26N/A37.92
Cashflow$1.51 per share$0.56 per shareN/AN/AN/A
Price / Cash42.5637.52N/AN/AN/A
Book Value$8.51 per share$6.89 per share$7.14 per share$6.10 per share$3.49 per share
Price / Book7.573.047.42N/A6.64
Profitability
Net Income$-11,020,000.00$-196,620,000.00$-86,430,000.00$-77,270,000.00$-115,380,000.00
EPS$0.86$0.07($7.02)($1.58)($0.91)
Trailing P/E Ratio22.69N/AN/AN/A110.39
Forward P/E Ratio22.38298.86N/AN/AN/A
P/E Growth0.8212.74N/AN/AN/A
Net Margins29.95%-6.28%N/AN/A8.76%
Return on Equity (ROE)10.71%9.35%-33.97%-35.81%4.51%
Return on Assets (ROA)4.88%5.50%-31.49%-27.52%2.25%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.78%0.25%N/A0.25%N/A
Current Ratio7.63%2.71%19.51%7.30%5.02%
Quick Ratio6.84%2.39%19.49%7.30%4.93%
Ownership Information
Institutional Ownership PercentageN/A97.30%46.98%N/A3.06%
Insider Ownership Percentage5.80%4.49%31.50%41.40%N/A
Miscellaneous
Employees6242,24516691615
Shares Outstanding43.86 million159.24 million54.95 million61.78 million131.56 million
Next Earnings Date5/4/2021 (Confirmed)4/28/2021 (Confirmed)5/12/2021 (Estimated)5/5/2021 (Estimated)5/5/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableNot Optionable
SourceHeadline
Biotalys appoints new chairman of the boardBiotalys appoints new chairman of the board
freshplaza.com - April 21 at 9:52 AM
Biotalys Appoints Simon Moroney as Chairman of the BoardBiotalys Appoints Simon Moroney as Chairman of the Board
uk.finance.yahoo.com - April 20 at 8:18 AM
MorphoSys AG (NASDAQ:MOR) Given Average Recommendation of "Hold" by AnalystsMorphoSys AG (NASDAQ:MOR) Given Average Recommendation of "Hold" by Analysts
americanbankingnews.com - April 17 at 2:56 AM
MorphoSys AG ADR (MOR)MorphoSys AG ADR (MOR)
investing.com - April 15 at 8:18 PM
MorphoSys AG (NASDAQ:MOR) Short Interest Down 55.3% in MarchMorphoSys AG (NASDAQ:MOR) Short Interest Down 55.3% in March
americanbankingnews.com - April 14 at 11:56 AM
MorphoSys-Aktie aktuell: MorphoSys mit positiven VorzeichenMorphoSys-Aktie aktuell: MorphoSys mit positiven Vorzeichen
finanzen.net - April 12 at 10:46 PM
DEUTSCHE BANK belässt MORPHOSYS auf BuyDEUTSCHE BANK belässt MORPHOSYS auf 'Buy'
finanznachrichten.de - April 10 at 6:04 PM
Biotech Report: MorphoSys (MOPR) und Qiagen (QIA) kletternBiotech Report: MorphoSys (MOPR) und Qiagen (QIA) klettern
finanznachrichten.de - April 9 at 7:34 PM
Biotech Report Biontech (22UA) und Vita34 (V3V) klettern; MorphoSys (MOR) kaum bewegtBiotech Report Biontech (22UA) und Vita34 (V3V) klettern; MorphoSys (MOR) kaum bewegt
wallstreet-online.de - April 9 at 7:34 PM
MorphoSys (MOR) "Buy" Rating Reaffirmed at Deutsche Bank AktiengesellschaftMorphoSys' (MOR) "Buy" Rating Reaffirmed at Deutsche Bank Aktiengesellschaft
americanbankingnews.com - April 8 at 4:54 PM
MorphoSys (NASDAQ:MOR) Sets New 52-Week Low at $21.27MorphoSys (NASDAQ:MOR) Sets New 52-Week Low at $21.27
americanbankingnews.com - March 30 at 6:38 PM
MorphoSys, Incyte are touting Monjuvis potential down the line—but COVID-19 is slowing its launch nowMorphoSys, Incyte are touting Monjuvi's potential down the line—but COVID-19 is slowing its launch now
fiercepharma.com - March 30 at 1:36 PM
MorphoSys (NASDAQ:MOR) Shares Gap Down to $22.32MorphoSys (NASDAQ:MOR) Shares Gap Down to $22.32
americanbankingnews.com - March 29 at 11:48 AM
MorphoSys (NASDAQ:MOR) Stock Rating Reaffirmed by SVB LeerinkMorphoSys (NASDAQ:MOR) Stock Rating Reaffirmed by SVB Leerink
americanbankingnews.com - March 29 at 9:30 AM
Biotech Report MorphoSys (MOR) und Qiagen (QIA) ziehen anBiotech Report MorphoSys (MOR) und Qiagen (QIA) ziehen an
wallstreet-online.de - March 21 at 5:37 PM
Morphosys am Tag nach dem Kursrutsch - das sagen jetzt die AnalystenMorphosys am Tag nach dem Kursrutsch - das sagen jetzt die Analysten
finanznachrichten.de - March 18 at 8:20 AM
Morphosys Aktie stürzt nach schwacher Prognose ab - Analysten bleiben gelassenerMorphosys Aktie stürzt nach schwacher Prognose ab - Analysten bleiben gelassener
4investors.de - March 18 at 8:20 AM
Mitgründer und Ex-Chef von Morphosys Was Simon Moroney heute machtMitgründer und Ex-Chef von Morphosys Was Simon Moroney heute macht
manager-magazin.de - March 18 at 8:20 AM
Morphosys profitiert von AllianzenMorphosys profitiert von Allianzen
aerztezeitung.de - March 18 at 8:20 AM
Morphosys-Aktie erholt - Analysten bleiben nach Ausblick gelassenMorphosys-Aktie erholt - Analysten bleiben nach Ausblick gelassen
finanzen.net - March 18 at 8:20 AM
MorphoSys AG (MOR) Q4 2020 Earnings Call TranscriptMorphoSys AG (MOR) Q4 2020 Earnings Call Transcript
fool.com - March 17 at 4:13 AM
MorphoSys AG veröffentlicht Ergebnisse des Geschäftsjahres 2020MorphoSys AG veröffentlicht Ergebnisse des Geschäftsjahres 2020
dgap.de - March 17 at 12:25 AM
AKTIE IM FOKUS: Aussicht auf wenig Umsatz und Verlust belastet MorphosysAKTIE IM FOKUS: Aussicht auf wenig Umsatz und Verlust belastet Morphosys
finanznachrichten.de - March 17 at 12:25 AM
MorphoSys: Anleger in AufruhrMorphoSys: Anleger in Aufruhr
finanznachrichten.de - March 17 at 12:25 AM
MorphoSys-Aktie nähert sich vorbörslich Zwölfmonatstief: MorphoSys plant 2021 mit höheren AufwendungenMorphoSys-Aktie nähert sich vorbörslich Zwölfmonatstief: MorphoSys plant 2021 mit höheren Aufwendungen
msn.com - March 17 at 12:25 AM
DateCompanyBrokerageAction
4/15/2021Pacira BioSciencesBerenberg BankInitiated Coverage
3/8/2021Pacira BioSciencesHC WainwrightBoost Price Target
2/26/2021Pacira BioSciencesBarclaysBoost Price Target
2/11/2021Pacira BioSciencesNorthland SecuritiesDowngrade
1/21/2021Pacira BioSciencesSVB LeerinkDowngrade
1/20/2021Pacira BioSciencesPiper SandlerBoost Price Target
1/8/2021Pacira BioSciencesNeedham & Company LLCBoost Price Target
1/6/2021Pacira BioSciencesRoyal Bank of CanadaBoost Price Target
11/2/2020Pacira BioSciencesWedbushLower Price Target
9/30/2020Pacira BioSciencesJefferies Financial GroupBoost Price Target
8/14/2020Pacira BioSciencesTruistBoost Price Target
1/7/2021AlkermesMizuhoBoost Price Target
10/7/2020AlkermesJPMorgan Chase & Co.Reiterated Rating
9/30/2020AlkermesBank of AmericaLower Price Target
7/30/2020AlkermesThe Goldman Sachs GroupDowngrade
4/29/2020AlkermesStifel NicolausLower Price Target
4/2/2020AlkermesMorgan StanleyLower Price Target
2/14/2020AlkermesCowenReiterated Rating
1/31/2020AlkermesWolfe ResearchUpgrade
2/8/2021Viela BioGuggenheimDowngrade
12/15/2020Rocket PharmaceuticalsUBS GroupInitiated Coverage
12/10/2020Rocket PharmaceuticalsEvercore ISIBoost Price Target
12/8/2020Rocket PharmaceuticalsChardan CapitalBoost Price Target
12/8/2020Rocket PharmaceuticalsOppenheimerDowngrade
10/16/2020Rocket PharmaceuticalsLifesci CapitalReiterated Rating
8/5/2020Rocket PharmaceuticalsCi CapitalReiterated Rating
5/6/2020Rocket PharmaceuticalsWilliam BlairReiterated Rating
4/8/2021MorphoSysDeutsche Bank AktiengesellschaftReiterated Rating
12/7/2020MorphoSysSmith Barney CitigroupReiterated Rating
8/10/2020MorphoSysCitigroupInitiated Coverage
5/12/2020MorphoSysHSBCUpgrade
11/5/2018MorphoSysPiper Jaffray CompaniesInitiated Coverage
(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.